Cardiomyopathy: Difference between revisions

	Cardiomyopathy Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Cardiomyopathy from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Guidelines
2023 ESC Guideline Recommendations
2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy
Case Studies
Case #1
Cardiomyopathy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Cardiomyopathy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Cardiomyopathy
CDC on Cardiomyopathy
Cardiomyopathy in the news
Blogs on Cardiomyopathy
Directions to Hospitals Treating Cardiomyopathy
Risk calculators and risk factors for Cardiomyopathy

	Cardiomyopathy;
	Opened left ventricle of heart shows a thickened, dilated left ventricle with subendocardial fibrosis manifested as increased whiteness of endocardium {Autopsy findings}. ; Image courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology

Latest revision as of 07:04, 13 November 2023

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Lina Ya'qoub,MD; Mahshid Mir, M.D. [2], Cafer Zorkun, M.D., Ph.D. [3], Raviteja Guddeti, M.B.B.S. [4]; Edzel Lorraine Co, DMD, MD [5]

Synonyms and keywords: Myocardiopathy; cardiac muscle disease; heart muscle disease.

@@ Line 1: / Line 1: @@
 __NOTOC__
-'''For patient information click [[Cardiomyopathy (patient information)|here]]'''
 {{Infobox_Disease |
    Name           = {{PAGENAME}} |
@@ Line 9: / Line 7: @@
 {{Cardiomyopathy}}
-{{CMG}};{{AE}}  [[User:Lina Ya'qoub|Lina Ya'qoub]], MD
+{{CMG}}; {{AE}} [[User:Lina Ya'qoub|Lina Ya'qoub,MD]]; {{MIR}}, {{CZ}}, {{RT}}; {{EdzelCo}}
- {{AE}}  [[User:Lina Ya'qoub|Lina Ya'qoub]]; {{AE}}<nowiki>{{AE}}</nowiki>  <nowiki></nowiki>MD {{CZ}}, {{RT}};
@@ Line 29: / Line 26: @@
 [[Cardiomyopathy medical therapy|Medical Therapy]] | [[Cardiomyopathy surgery|Surgery]] | [[Cardiomyopathy primary prevention|Primary Prevention]] | [[Cardiomyopathy secondary prevention|Secondary Prevention]] | [[Cardiomyopathy cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Cardiomyopathy future or investigational therapies|Future or Investigational Therapies]]
+==Guidelines==
+[[Cardiomyopathy 2023 ESC Guideline Recommendations|2023 ESC Guideline Recommendations]] | [[Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy|2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy]]
 == Case Studies ==
@@ Line 56: / Line 56: @@
 [[Category:Up-To-Date cardiology]]
 [[Category:Disease]]
+==References==


Cardiomyopathy
Opened left ventricle of heart shows a thickened, dilated left ventricle with subendocardial fibrosis manifested as increased whiteness of endocardium {Autopsy findings}. Image courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology